A Randomized, Double-blind, Parallel group, Placebo-controlled Study to investigate the efficacy, safety, and tolerability of ML-004 in adolescents and adults with autism spectrum disorders (ASD)
The IRIS Autism Trial
Sponsor: Maplight Therapeutics, Inc.
Enrolling: Male and Female Patients
Study Length: 26 Weeks
Clinic Visits: 10
IRB Number: 8471
U.S. Govt. ID: NCT05081245
Contact: Suvekcha Bhattachan: 914-997-5587 / suvekcha.bhattachan@nyspi.columbia.edu
Additional Study Information: This study will examine the possible benefits of an investigational drug called ML-004 in adolescents and adults diagnosed with autism spectrum disorder (ASD). We are currently recruiting adult participants (18-45 years). Participation will involve ten visits to the Center for Autism and the Developing Brain in White Plains, NY over a period of 26 weeks. This will allow the study team to assess participants' general health, perform developmental testing and provide study related medical care. You will not have to pay for any study related treatments, lab tests or assessments. You will receive $50 in reimbursements for in-clinic study visits and up to $40 in travel reimbursements.
Jeremy Veenstra-VanderWeele, MD
Do You Qualify?
Is the participant between the ages of 18 and 45? Yes No
Has the participant been diagnosed with Autism Spectrum Disorder? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Suvekcha Bhattachan